Serotype replacement in invasive pneumococcal disease: Where do we go from here?

Journal of Infectious Diseases

Volumn 196, Issue 9, 2007, Pages 1282-1284

  Hanage, W P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCAL CONJUGATE VACCINE 7; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIUM CARRIER; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENINGITIS; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; CLASSIFICATION; IMMUNOLOGY; MICROBIOLOGY; NOTE; STREPTOCOCCUS INFECTION; VACCINATION;

HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 38449088775     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/521630     Document Type: Editorial

References (13)

1. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999; 17(Suppl 2):S28-36.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
3. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9.
4. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007; 195:347-52.
5. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54 (in this issue).
6. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51.
7. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45:1225-33.
8. Hedlund J, Sorberg M, Henriques Normark B, Kronvall G. Capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae among children in Sweden. Scand J Infect Dis 2003; 35:452-8.
9. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcalserotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116:e408-13.
10. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9.
11. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190:1203-11.
12. Beall B, McEllistrem MC, Gertz RE Jr, et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006; 44:999-1017.
13. Hanage WP, Auranen K, Syrjanen R, et al. Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 2004; 72:76-81.